CAJ | 학술논문

目的观察注射用长春西汀对老年冠心病患者血浆高敏 C 反应蛋白(hs-CRP)和白细胞介素-6(IL-6)的影响.方法150例老年冠心病患者随机分为对照组50例,给予常规药物治疗;30mg 治疗组50例,在常规药物治疗的基础上运用30mg 长春西汀;50mg 治疗组50例,在常规药物治疗的基础上运用50mg长春西汀.9天为一疗程.结果①30mg 治疗组及50mg 治疗组有效率分别与对照组比较,有效率具有显著性差异,P 均<O.05.②治疗前三组 hs-CRP 分别为4.70±0.68 mg/ml (对照组),4.76±0.86 mg/ml (30mg 治疗组),4.82±0.94 mg/ml (50mg 治疗组);治疗后分别依次为4.42±0.59mg/m1,4.18±0.93mg/ml,3.57±0.84mg/ml.治疗前三组 IL-6分别为6.41±0.90 pg/ml,6.52±0.98 pg/ml,6.48±1.30pg/ml;治疗后依次分别为5.89±0.87pg/ml,4.89±0.77pg/ml,4.12±0.96pg/ml.治疗前三组间 hs-CRP、IL-6两两比较及治疗组(30mg 治疗组+50mg 治疗组)与对照组比较,无显著性差异.治疗后三组间 hs-CRP 两两比较无显著性差异,但是,30mg 治疗组+50mg 治疗组与对照组比较,有显著性差异,P<O.05.治疗后 IL-6比较:30mg 治疗组显著低于对照组,P<O.05;显著高于50mg 治疗组,P<O.05,且对照组极显著高于50mg 治疗组,P<O.01.③血清 hs-CRP 水平与 IL-6水平呈正相关(r=0.173,P=0.035).结论注射用长春西汀能显著降低老年冠心病患者血浆 hs-CRP 及 IL-6,且剂量不同降低 IL-6的效果不同.
목적관찰주사용장춘서정대노년관심병환자혈장고민 C 반응단백(hs-CRP)화백세포개소-6(IL-6)적영향.방법150례노년관심병환자수궤분위대조조50례,급여상규약물치료;30mg 치료조50례,재상규약물치료적기출상운용30mg 장춘서정;50mg 치료조50례,재상규약물치료적기출상운용50mg장춘서정.9천위일료정.결과①30mg 치료조급50mg 치료조유효솔분별여대조조비교,유효솔구유현저성차이,P 균<O.05.②치료전삼조 hs-CRP 분별위4.70±0.68 mg/ml (대조조),4.76±0.86 mg/ml (30mg 치료조),4.82±0.94 mg/ml (50mg 치료조);치료후분별의차위4.42±0.59mg/m1,4.18±0.93mg/ml,3.57±0.84mg/ml.치료전삼조 IL-6분별위6.41±0.90 pg/ml,6.52±0.98 pg/ml,6.48±1.30pg/ml;치료후의차분별위5.89±0.87pg/ml,4.89±0.77pg/ml,4.12±0.96pg/ml.치료전삼조간 hs-CRP、IL-6량량비교급치료조(30mg 치료조+50mg 치료조)여대조조비교,무현저성차이.치료후삼조간 hs-CRP 량량비교무현저성차이,단시,30mg 치료조+50mg 치료조여대조조비교,유현저성차이,P<O.05.치료후 IL-6비교:30mg 치료조현저저우대조조,P<O.05;현저고우50mg 치료조,P<O.05,차대조조겁현저고우50mg 치료조,P<O.01.③혈청 hs-CRP 수평여 IL-6수평정정상관(r=0.173,P=0.035).결론주사용장춘서정능현저강저노년관심병환자혈장 hs-CRP 급 IL-6,차제량불동강저 IL-6적효과불동.
objective To investigate the influence of the injectable vinpocetine to plasma inflammatory factor- high sensitivity C reactive protein (hs - CRP) and interleukina 6 (IL -6) in elderly patients with coronary heart disease (CHD). Methods 150 cases elderly coronary heart disease patients were randomly divided into treatment group 30 mg (fifty cases)、50 mg (fifty cases) and control group (fifty cases).The control group was given conventional western medicine treatment; The treatment group was given the injectable vinpocetine (divided into 30 mg group and 50 mg group), on the basis of the conventional western medicine treatment , 1 time/day. Three groups were treated 9 days for one period. Results (1) 30 mg group efficient rate(78.0%) and 50 mg group effective rate (90.0%) were significantly better than the control group (54.0%), P < 0.05; (2)high sensitivity C reactive protein in three groups before treatment was respectively 4.70±0.68mg/ml (control group), 4.76±0.86mg/ml (30mg treatment group), 4.82±0.94mg/ml(50mg treatment group); after treatment was respectively 4.42±0.59mg/m1, 4.18±0.93mg/ml, 3.57±0.84mg/ml ]. Interleukin 6 in three groups before treatment was respectively 6.41±0.90pg/ml , 6.52±0.98 pg/ml, 6.48±1.30pg/ml; after treatment was respectively 5.89±0.87pg/ml,4.89±0.77pg/ml,4.12±0.96pg/ml. hs - CRP, IL – 6 Before treatment in comparison of the three groups and between 30 mg group ,50 mg group and control group was no significantly difference. after treatment , in comparison of the three groups were no significantly difference, then 30 mg group ,50 mg group were significantly difference than the control group, P<O.05, moreover , the control group was highly significantly difference than 50 mg treatment group, P<O.01. (3) plasma inflammatory factor- high sensitivity C reactive protein (hs - CRP) and interleukina 6 (IL - 6) were positively correlated(r=0.173,P=0.035). Conclusion the injectable vinpocetine can obviously reduce the elderly patients with coronary heart disease (CHD) in plasma inflammatory factor -high sensitivity C reactive protein (hs - CRP) and interleukina 6 (IL - 6) , and different dose has different effect in reduce interleukina 6 (IL - 6).